Compare Norfolk Southern Corporation (NSC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Norfolk Southern Corporation trades at $323.3 (market cap $72.62B), while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: Norfolk Southern Corporation pays a 1.67% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Norfolk Southern Corporation nearer its low. Which is the better fit depends on your goals.
| NSC | XBI | |
|---|---|---|
Market Cap | $72.62B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $352.98 | $169.55 |
52-Week Low | $272.36 | $93.43 |
Enterprise Value | $88.16B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $327.92, down 0.47% on the day, with technical indicators showing a bearish trend near key support at $327. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.52 surpassing estimates of $3.32, while profitability remains robust with a net income margin of 21.02%. A proposed merger with Union Pacific, under STB review, dominates recent news, alongside institutional buying interest.
NSC presents a mixed outlook: solid fundamentals and merger potential offer upside to the $369.67 consensus target, but regulatory hurdles and a bearish technical setup pose near-term risks. Investors should weigh the company's earnings momentum against integration uncertainties and market volatility.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
